1,2,5,8-tetrahydroxy anthraquinone has been researched along with Alzheimer Disease in 2 studies
1,2,5,8-tetrahydroxy anthraquinone: structure in first source
quinalizarin : A tetrahydroxyanthraquinone having the four hydroxy groups at the 1-, 2-, 5- and 8-positions.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bulic, B | 1 |
| Pickhardt, M | 1 |
| Mandelkow, E | 1 |
| Smith, B | 1 |
| Medda, F | 1 |
| Gokhale, V | 1 |
| Dunckley, T | 1 |
| Hulme, C | 1 |
2 reviews available for 1,2,5,8-tetrahydroxy anthraquinone and Alzheimer Disease
| Article | Year |
|---|---|
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Hydrogen Bonding; Models, Molecular; P | 2013 |
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Topics: Alzheimer Disease; Animals; Anthraquinones; Biomedical Research; Carbolines; Catechin; Chromosomes, | 2012 |